KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Accured Expenses (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Change in Accured Expenses readings, the most recent being $12.7 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 100.41% to $12.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.2 million, a 70.23% increase, with the full-year FY2025 number at $31.2 million, up 70.23% from a year prior.
  • Change in Accured Expenses hit $12.7 million in Q4 2025 for Esperion Therapeutics, down from $21.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $25.0 million in Q1 2021 to a low of -$21.8 million in Q2 2021.
  • Median Change in Accured Expenses over the past 5 years was $2.8 million (2021), compared with a mean of $4.1 million.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 394.93% in 2021 and later soared 690.34% in 2023.
  • Esperion Therapeutics' Change in Accured Expenses stood at -$789000.0 in 2021, then surged by 255.77% to $1.2 million in 2022, then surged by 566.8% to $8.2 million in 2023, then fell by 22.55% to $6.3 million in 2024, then surged by 100.41% to $12.7 million in 2025.
  • The last three reported values for Change in Accured Expenses were $12.7 million (Q4 2025), $21.2 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.